Which patients could benefit the most from bioresorbable vascular scaffold implant: From clinical trials to clinical practice

A. Latib, C. Costopoulos, T. Naganuma, A. Colombo

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations

Abstract

Bioresorbable scaffold technology has evolved over the last few years with a number of devices either available or under clinical and preclinical investigation. The absence of a permanent metallic segment in the treated vessel wall has the potential of addressing some of the issues still encountered with metallic drug-eluting stents (DES) despite improvements in stent platform, polymer and drug elution. To date however, the use of bioresorbable vascular scaffolds (BVS) has largely been restricted to patients recruited into clinical trials with a relatively small number of "real-world" patients treated with these devices. Here we explore the issue of BVS use in "real-world" patients and try to identify, on the basis of our experience, the subset of patients that could benefit the most.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalMinerva Cardioangiologica
Volume61
Issue number3
StatePublished - Jun 2013
Externally publishedYes

Keywords

  • Drug-eluting stents
  • Myocardial revascularization
  • Stents
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Which patients could benefit the most from bioresorbable vascular scaffold implant: From clinical trials to clinical practice'. Together they form a unique fingerprint.

Cite this